Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 148

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 148
---
)  |
| Dr. Susan Alpert        |     |  76 |     | Director Nominee(1)(2)  |

| (1) | Indicates an Independent Director and a member of our Audit Committee and Compensation Committee. |

| (2) | Each of Mr. Ben-Elazar and Dr. Alpert will become a director at the                                                                       
 effective time of the registration statement to which this prospectus relates, and will serve as an external director under the Companies 
 Law subject to the ratification of his/her appointment at a general meeting of our shareholders to be held following the completion of    
 this offering.                                                                                                                            |

Dr. Ehud Geller, Chairman of the Board of Directors

Dr.
Ehud Geller has served as the Chairman of our Board of Directors since 2007. Since 1995, Dr. Geller has served as the General Partner
of Medica Venture Partners. Between 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva Pharmaceutical
Industries Ltd. (NYSE:TEVA) and Executive VP of the Teva Group. At Teva, he led the acquisition of Ikapharm Ltd. He served as the President
and Chief Executive Officer of Interpharm Laboratories, Ltd. from 1985 to 1990. During these years he also served as head of the Israeli
Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange. Dr. Geller has a B.Sc. degree in Chemical
Engineering, an MBA degree from Columbia University/Drexel Institute and a Ph.D. degree in Pharmaceutical/Chemical Engineering from Drexel
Institute, Philadelphia. Since 1995, he has been the General Partner of Medica Venture Partners. Mr. Geller was selected to serve
on the board of directors as Chairman due to his significant experience leading and growing companies in the pharmaceutical industry and
his significant leadership experience. His experience leading the Company’s management and the depth of his knowledge of our business
enable him to provide valuable leadership on complex business matters that we face on an ongoing basis. Dr. Geller will devote approximately
50% of his time to the Company, as an executive Chairman, upon completion of this offering as he also is currently employed by Medica
Venture Partners.

Dr. Eli Hazum, Chief Executive Officer

Dr. Eli Hazum has served
as our Chief Executive Officer since October 2021. He has been a partner